Company intelligence

IMRX

Immuneering Corporation · NASDAQ · Healthcare

Price$5.23+0.97% · +$0.05

Market cap189.86MEquity value

P / E-5.0Trailing ratio

Volume362.88KLatest session

Market data

IMRX price chart

TradingView

Related signals

1 min delayed

Browse public IMRX signals with their source context and measured market impact. Open any signal for its permanent analysis page.

IMRXJan 8, 2026-18.30% since signal

Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower

Immuneering's stock is down 26.53% after trial data release. Atebimetinib combo shows significant overall survival versus chemotherapy. Progression-free survival was better with atebimetinib than chemotherapy. Upcoming trial results expected in 2026 may influence future stock price. Current cash flow sufficient to fund operations into 2029.

View signal analysis

IMRXJan 7, 2025-31.97% since signal

Why Is Immuneering Stock Trading Higher On Tuesday?

IMM-1-104 shows 43% response rate in modified gemcitabine treatment. Favorable tolerability for IMM-1-104 with modified FOLFIRINOX reported. Disease control in second-line pancreatic cancer achieved by 52% of patients. Plans to expand Phase 2a trial with three additional combination arms. Stock rose 61.90% during premarket after data release.

View signal analysis

Research